{"id":2373,"date":"2021-07-13T21:44:48","date_gmt":"2021-07-13T19:44:48","guid":{"rendered":"https:\/\/www.institut-myologie.org\/imotion\/?p=2373"},"modified":"2021-07-13T22:01:59","modified_gmt":"2021-07-13T20:01:59","slug":"dmd-demarrage-a-i-motion-dessais-avec-le-pamrevlumab-chez-des-patients-ambulants-et-non-ambulants","status":"publish","type":"post","link":"https:\/\/www.institut-myologie.org\/imotion\/2021\/07\/13\/dmd-demarrage-a-i-motion-dessais-avec-le-pamrevlumab-chez-des-patients-ambulants-et-non-ambulants\/","title":{"rendered":"DMD : d\u00e9marrage \u00e0 I-Motion d’essais avec le pamrevlumab chez des patients ambulants et non ambulants"},"content":{"rendered":"\n

I-Motion recrute des patients atteints de myopathie de Duchenne pour participer \u00e0 deux essais pharmacologiques destin\u00e9s \u00e0 tester un anticorps monoclonal antifibrotique, le pamrevlumab (ou FG-3019), d\u00e9velopp\u00e9 par le laboratoire FibroGen.<\/p>\n\n\n\n

Ces essais de phase III ont pour objectif d\u2019\u00e9valuer la tol\u00e9rance, l\u2019innocuit\u00e9 et l\u2019efficacit\u00e9 sur les membres sup\u00e9rieurs, les fonctions respiratoire et cardiaque, du pamrevlumab administr\u00e9 par perfusion intraveineuse en combinaison avec des cortico\u00efdes par voie orale, chez des gar\u00e7ons atteints de DMD, \u00e2g\u00e9s de plus de 12 ans, ambulants (essai FGCL-3019-094) ou non ambulants (essai FGCL-3019-093).<\/p>\n\n\n\n

Le Dr Silvana De Lucia est l\u2019investigatrice principale dans ces deux essais sur le site I-Motion.<\/p>\n\n\n\n

> En savoir plus sur l\u2019essai FGCL-3019-094<\/a> et l\u2019essai FGCL-3019-093<\/a> (site AFM-T\u00e9l\u00e9thon)<\/p>\n","protected":false},"excerpt":{"rendered":"

I-Motion recrute des patients atteints de myopathie de Duchenne pour participer \u00e0 deux essais pharmacologiques destin\u00e9s \u00e0 tester un anticorps monoclonal antifibrotique, le pamrevlumab (ou FG-3019), d\u00e9velopp\u00e9 par le laboratoire FibroGen. Ces essais de phase III ont pour objectif d\u2019\u00e9valuer la tol\u00e9rance, l\u2019innocuit\u00e9 et l\u2019efficacit\u00e9 sur les membres sup\u00e9rieurs, les fonctions respiratoire et cardiaque, du … Continued<\/a><\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-2373","post","type-post","status-publish","format-standard","hentry","category-non-classifiee"],"acf":[],"yoast_head":"\nDMD : d\u00e9marrage \u00e0 I-Motion d'essais avec le pamrevlumab chez des patients ambulants et non ambulants - I-Motion<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.institut-myologie.org\/imotion\/2021\/07\/13\/dmd-demarrage-a-i-motion-dessais-avec-le-pamrevlumab-chez-des-patients-ambulants-et-non-ambulants\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"DMD : d\u00e9marrage \u00e0 I-Motion d'essais avec le pamrevlumab chez des patients ambulants et non ambulants - I-Motion\" \/>\n<meta property=\"og:description\" content=\"I-Motion recrute des patients atteints de myopathie de Duchenne pour participer \u00e0 deux essais pharmacologiques destin\u00e9s \u00e0 tester un anticorps monoclonal antifibrotique, le pamrevlumab (ou FG-3019), d\u00e9velopp\u00e9 par le laboratoire FibroGen. Ces essais de phase III ont pour objectif d\u2019\u00e9valuer la tol\u00e9rance, l\u2019innocuit\u00e9 et l\u2019efficacit\u00e9 sur les membres sup\u00e9rieurs, les fonctions respiratoire et cardiaque, du … Continued\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.institut-myologie.org\/imotion\/2021\/07\/13\/dmd-demarrage-a-i-motion-dessais-avec-le-pamrevlumab-chez-des-patients-ambulants-et-non-ambulants\/\" \/>\n<meta property=\"og:site_name\" content=\"I-Motion\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-13T19:44:48+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-13T20:01:59+00:00\" \/>\n<meta name=\"author\" content=\"Anne Berthomier\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Anne Berthomier\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.institut-myologie.org\/imotion\/2021\/07\/13\/dmd-demarrage-a-i-motion-dessais-avec-le-pamrevlumab-chez-des-patients-ambulants-et-non-ambulants\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.institut-myologie.org\/imotion\/2021\/07\/13\/dmd-demarrage-a-i-motion-dessais-avec-le-pamrevlumab-chez-des-patients-ambulants-et-non-ambulants\/\"},\"author\":{\"name\":\"Anne Berthomier\",\"@id\":\"https:\/\/www.institut-myologie.org\/imotion\/#\/schema\/person\/ecf0b87715a026a200491fe2d7649def\"},\"headline\":\"DMD : d\u00e9marrage \u00e0 I-Motion d’essais avec le pamrevlumab chez des patients ambulants et non ambulants\",\"datePublished\":\"2021-07-13T19:44:48+00:00\",\"dateModified\":\"2021-07-13T20:01:59+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.institut-myologie.org\/imotion\/2021\/07\/13\/dmd-demarrage-a-i-motion-dessais-avec-le-pamrevlumab-chez-des-patients-ambulants-et-non-ambulants\/\"},\"wordCount\":151,\"publisher\":{\"@id\":\"https:\/\/www.institut-myologie.org\/imotion\/#organization\"},\"articleSection\":[\"Non classifi\u00e9(e)\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.institut-myologie.org\/imotion\/2021\/07\/13\/dmd-demarrage-a-i-motion-dessais-avec-le-pamrevlumab-chez-des-patients-ambulants-et-non-ambulants\/\",\"url\":\"https:\/\/www.institut-myologie.org\/imotion\/2021\/07\/13\/dmd-demarrage-a-i-motion-dessais-avec-le-pamrevlumab-chez-des-patients-ambulants-et-non-ambulants\/\",\"name\":\"DMD : d\u00e9marrage \u00e0 I-Motion d'essais avec le pamrevlumab chez des patients ambulants et non ambulants - I-Motion\",\"isPartOf\":{\"@id\":\"https:\/\/www.institut-myologie.org\/imotion\/#website\"},\"datePublished\":\"2021-07-13T19:44:48+00:00\",\"dateModified\":\"2021-07-13T20:01:59+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.institut-myologie.org\/imotion\/2021\/07\/13\/dmd-demarrage-a-i-motion-dessais-avec-le-pamrevlumab-chez-des-patients-ambulants-et-non-ambulants\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.institut-myologie.org\/imotion\/2021\/07\/13\/dmd-demarrage-a-i-motion-dessais-avec-le-pamrevlumab-chez-des-patients-ambulants-et-non-ambulants\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.institut-myologie.org\/imotion\/2021\/07\/13\/dmd-demarrage-a-i-motion-dessais-avec-le-pamrevlumab-chez-des-patients-ambulants-et-non-ambulants\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.institut-myologie.org\/imotion\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"DMD : d\u00e9marrage \u00e0 I-Motion d’essais avec le pamrevlumab chez des patients ambulants et non ambulants\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.institut-myologie.org\/imotion\/#website\",\"url\":\"https:\/\/www.institut-myologie.org\/imotion\/\",\"name\":\"I-Motion\",\"description\":\"Plateforme d'essais cliniques p\u00e9diatriques pour les maladies neuromusculaires\",\"publisher\":{\"@id\":\"https:\/\/www.institut-myologie.org\/imotion\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.institut-myologie.org\/imotion\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.institut-myologie.org\/imotion\/#organization\",\"name\":\"Institut I-Motion\",\"url\":\"https:\/\/www.institut-myologie.org\/imotion\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.institut-myologie.org\/imotion\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.institut-myologie.org\/imotion\/wp-content\/uploads\/2016\/08\/logoImotion.png\",\"contentUrl\":\"https:\/\/www.institut-myologie.org\/imotion\/wp-content\/uploads\/2016\/08\/logoImotion.png\",\"width\":150,\"height\":51,\"caption\":\"Institut I-Motion\"},\"image\":{\"@id\":\"https:\/\/www.institut-myologie.org\/imotion\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.institut-myologie.org\/imotion\/#\/schema\/person\/ecf0b87715a026a200491fe2d7649def\",\"name\":\"Anne Berthomier\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.institut-myologie.org\/imotion\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/86282695a210f7767b59efc8eb542fb81270ad9c1a9d8bb3bccd9ab2f96782e6?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/86282695a210f7767b59efc8eb542fb81270ad9c1a9d8bb3bccd9ab2f96782e6?s=96&d=mm&r=g\",\"caption\":\"Anne Berthomier\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"DMD : d\u00e9marrage \u00e0 I-Motion d'essais avec le pamrevlumab chez des patients ambulants et non ambulants - I-Motion","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.institut-myologie.org\/imotion\/2021\/07\/13\/dmd-demarrage-a-i-motion-dessais-avec-le-pamrevlumab-chez-des-patients-ambulants-et-non-ambulants\/","og_locale":"fr_FR","og_type":"article","og_title":"DMD : d\u00e9marrage \u00e0 I-Motion d'essais avec le pamrevlumab chez des patients ambulants et non ambulants - I-Motion","og_description":"I-Motion recrute des patients atteints de myopathie de Duchenne pour participer \u00e0 deux essais pharmacologiques destin\u00e9s \u00e0 tester un anticorps monoclonal antifibrotique, le pamrevlumab (ou FG-3019), d\u00e9velopp\u00e9 par le laboratoire FibroGen. Ces essais de phase III ont pour objectif d\u2019\u00e9valuer la tol\u00e9rance, l\u2019innocuit\u00e9 et l\u2019efficacit\u00e9 sur les membres sup\u00e9rieurs, les fonctions respiratoire et cardiaque, du … Continued","og_url":"https:\/\/www.institut-myologie.org\/imotion\/2021\/07\/13\/dmd-demarrage-a-i-motion-dessais-avec-le-pamrevlumab-chez-des-patients-ambulants-et-non-ambulants\/","og_site_name":"I-Motion","article_published_time":"2021-07-13T19:44:48+00:00","article_modified_time":"2021-07-13T20:01:59+00:00","author":"Anne Berthomier","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Anne Berthomier","Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.institut-myologie.org\/imotion\/2021\/07\/13\/dmd-demarrage-a-i-motion-dessais-avec-le-pamrevlumab-chez-des-patients-ambulants-et-non-ambulants\/#article","isPartOf":{"@id":"https:\/\/www.institut-myologie.org\/imotion\/2021\/07\/13\/dmd-demarrage-a-i-motion-dessais-avec-le-pamrevlumab-chez-des-patients-ambulants-et-non-ambulants\/"},"author":{"name":"Anne Berthomier","@id":"https:\/\/www.institut-myologie.org\/imotion\/#\/schema\/person\/ecf0b87715a026a200491fe2d7649def"},"headline":"DMD : d\u00e9marrage \u00e0 I-Motion d’essais avec le pamrevlumab chez des patients ambulants et non ambulants","datePublished":"2021-07-13T19:44:48+00:00","dateModified":"2021-07-13T20:01:59+00:00","mainEntityOfPage":{"@id":"https:\/\/www.institut-myologie.org\/imotion\/2021\/07\/13\/dmd-demarrage-a-i-motion-dessais-avec-le-pamrevlumab-chez-des-patients-ambulants-et-non-ambulants\/"},"wordCount":151,"publisher":{"@id":"https:\/\/www.institut-myologie.org\/imotion\/#organization"},"articleSection":["Non classifi\u00e9(e)"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.institut-myologie.org\/imotion\/2021\/07\/13\/dmd-demarrage-a-i-motion-dessais-avec-le-pamrevlumab-chez-des-patients-ambulants-et-non-ambulants\/","url":"https:\/\/www.institut-myologie.org\/imotion\/2021\/07\/13\/dmd-demarrage-a-i-motion-dessais-avec-le-pamrevlumab-chez-des-patients-ambulants-et-non-ambulants\/","name":"DMD : d\u00e9marrage \u00e0 I-Motion d'essais avec le pamrevlumab chez des patients ambulants et non ambulants - I-Motion","isPartOf":{"@id":"https:\/\/www.institut-myologie.org\/imotion\/#website"},"datePublished":"2021-07-13T19:44:48+00:00","dateModified":"2021-07-13T20:01:59+00:00","breadcrumb":{"@id":"https:\/\/www.institut-myologie.org\/imotion\/2021\/07\/13\/dmd-demarrage-a-i-motion-dessais-avec-le-pamrevlumab-chez-des-patients-ambulants-et-non-ambulants\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.institut-myologie.org\/imotion\/2021\/07\/13\/dmd-demarrage-a-i-motion-dessais-avec-le-pamrevlumab-chez-des-patients-ambulants-et-non-ambulants\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.institut-myologie.org\/imotion\/2021\/07\/13\/dmd-demarrage-a-i-motion-dessais-avec-le-pamrevlumab-chez-des-patients-ambulants-et-non-ambulants\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.institut-myologie.org\/imotion\/"},{"@type":"ListItem","position":2,"name":"DMD : d\u00e9marrage \u00e0 I-Motion d’essais avec le pamrevlumab chez des patients ambulants et non ambulants"}]},{"@type":"WebSite","@id":"https:\/\/www.institut-myologie.org\/imotion\/#website","url":"https:\/\/www.institut-myologie.org\/imotion\/","name":"I-Motion","description":"Plateforme d'essais cliniques p\u00e9diatriques pour les maladies neuromusculaires","publisher":{"@id":"https:\/\/www.institut-myologie.org\/imotion\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.institut-myologie.org\/imotion\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.institut-myologie.org\/imotion\/#organization","name":"Institut I-Motion","url":"https:\/\/www.institut-myologie.org\/imotion\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.institut-myologie.org\/imotion\/#\/schema\/logo\/image\/","url":"https:\/\/www.institut-myologie.org\/imotion\/wp-content\/uploads\/2016\/08\/logoImotion.png","contentUrl":"https:\/\/www.institut-myologie.org\/imotion\/wp-content\/uploads\/2016\/08\/logoImotion.png","width":150,"height":51,"caption":"Institut I-Motion"},"image":{"@id":"https:\/\/www.institut-myologie.org\/imotion\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.institut-myologie.org\/imotion\/#\/schema\/person\/ecf0b87715a026a200491fe2d7649def","name":"Anne Berthomier","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.institut-myologie.org\/imotion\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/86282695a210f7767b59efc8eb542fb81270ad9c1a9d8bb3bccd9ab2f96782e6?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/86282695a210f7767b59efc8eb542fb81270ad9c1a9d8bb3bccd9ab2f96782e6?s=96&d=mm&r=g","caption":"Anne Berthomier"}}]}},"_links":{"self":[{"href":"https:\/\/www.institut-myologie.org\/imotion\/wp-json\/wp\/v2\/posts\/2373","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.institut-myologie.org\/imotion\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.institut-myologie.org\/imotion\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.institut-myologie.org\/imotion\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.institut-myologie.org\/imotion\/wp-json\/wp\/v2\/comments?post=2373"}],"version-history":[{"count":8,"href":"https:\/\/www.institut-myologie.org\/imotion\/wp-json\/wp\/v2\/posts\/2373\/revisions"}],"predecessor-version":[{"id":2385,"href":"https:\/\/www.institut-myologie.org\/imotion\/wp-json\/wp\/v2\/posts\/2373\/revisions\/2385"}],"wp:attachment":[{"href":"https:\/\/www.institut-myologie.org\/imotion\/wp-json\/wp\/v2\/media?parent=2373"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.institut-myologie.org\/imotion\/wp-json\/wp\/v2\/categories?post=2373"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.institut-myologie.org\/imotion\/wp-json\/wp\/v2\/tags?post=2373"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}